Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BOLT
DateTimeSourceHeadlineSymbolCompany
21/05/202403:22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BOLTBolt Biotherapeutics Inc
16/05/202407:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
15/05/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
15/05/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
15/05/202406:05GlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamNASDAQ:BOLTBolt Biotherapeutics Inc
22/03/202407:05GlobeNewswire Inc.Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
07/03/202405:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
07/03/202405:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
27/02/202423:00GlobeNewswire Inc.Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
13/02/202413:41Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BOLTBolt Biotherapeutics Inc
07/02/202405:09Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
21/12/202323:30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:BOLTBolt Biotherapeutics Inc
14/12/202305:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
05/12/202323:00GlobeNewswire Inc.Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®NASDAQ:BOLTBolt Biotherapeutics Inc
10/11/202308:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
10/11/202308:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
10/11/202308:05GlobeNewswire Inc.Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
07/11/202323:00GlobeNewswire Inc.Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
24/10/202301:30GlobeNewswire Inc.Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressNASDAQ:BOLTBolt Biotherapeutics Inc
18/10/202322:00GlobeNewswire Inc.Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
17/10/202322:00GlobeNewswire Inc.Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersNASDAQ:BOLTBolt Biotherapeutics Inc
16/10/202322:00GlobeNewswire Inc.Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023NASDAQ:BOLTBolt Biotherapeutics Inc
28/09/202321:00GlobeNewswire Inc.Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersNASDAQ:BOLTBolt Biotherapeutics Inc
12/09/202322:05GlobeNewswire Inc.Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042NASDAQ:BOLTBolt Biotherapeutics Inc
06/09/202306:15GlobeNewswire Inc.Bolt Biotherapeutics to Participate in September Investor ConferencesNASDAQ:BOLTBolt Biotherapeutics Inc
08/08/202306:10GlobeNewswire Inc.Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
08/08/202306:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
08/08/202306:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
03/08/202321:30GlobeNewswire Inc.Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive CancerNASDAQ:BOLTBolt Biotherapeutics Inc
01/08/202307:27GlobeNewswire Inc.Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023NASDAQ:BOLTBolt Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BOLT